Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5171807
Max Phase: Preclinical
Molecular Formula: C28H38F2N6OS
Molecular Weight: 544.72
Associated Items:
ID: ALA5171807
Max Phase: Preclinical
Molecular Formula: C28H38F2N6OS
Molecular Weight: 544.72
Associated Items:
Canonical SMILES: Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccc(C#N)s1
Standard InChI: InChI=1S/C28H38F2N6OS/c1-17(2)26-34-33-18(3)36(26)22-14-20-4-5-21(15-22)35(20)13-10-24(25-7-6-23(16-31)38-25)32-27(37)19-8-11-28(29,30)12-9-19/h6-7,17,19-22,24H,4-5,8-15H2,1-3H3,(H,32,37)/t20-,21+,22-,24-/m0/s1
Standard InChI Key: YIRKPANMABMDIQ-KHUIQGCPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 544.72 | Molecular Weight (Monoisotopic): 544.2796 | AlogP: 5.88 | #Rotatable Bonds: 8 |
Polar Surface Area: 86.84 | Molecular Species: BASE | HBA: 7 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.96 | CX Basic pKa: 8.77 | CX LogP: 3.53 | CX LogD: 2.14 |
Aromatic Rings: 2 | Heavy Atoms: 38 | QED Weighted: 0.45 | Np Likeness Score: -0.88 |
1. Xie X, Zheng YG, Chen H, Li J, Luo RH, Chen L, Zheng CB, Zhang S, Peng P, Ma D, Yang LM, Zheng YT, Liu H, Wang J.. (2022) Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability., 65 (24.0): [PMID:36472561] [10.1021/acs.jmedchem.2c01383] |
Source(1):